Urinary beta-2-microglobulin does not serve as diagnostic tool for Minamata disease

Area of Science:

• Environmental Health
• Toxicology
• Clinical Chemistry

Background:

• Minamata disease, caused by methylmercury poisoning, presents diagnostic challenges.
• Establishing clear diagnostic criteria remains a significant medico-socio-legal issue.

Purpose of the Study:

• To evaluate the effectiveness of urinary beta-2-microglobulin (BMG) as a diagnostic marker for Minamata disease.
• To assess the utility of BMG in differentiating patients with Minamata disease from control subjects.

Main Methods:

• Study included 115 registered Minamata disease patients, 114 unregistered patients undergoing evaluation, and 82 control subjects.
• Urinary BMG levels, corrected for creatinine, were measured and compared across groups.
• Neurological scores were assessed and correlated with urinary BMG levels.

Main Results:

• No significant differences in urinary BMG levels were observed between registered patients, unregistered patients, and control subjects.
• A parallel increase in urinary BMG and neurological scores was noted in male patients, suggesting a potential dose-effect relationship.
• Hyper-beta-2-microglobulinuria, indicative of renal tubular dysfunction, was not a consistent or satisfactory diagnostic indicator.

Conclusions:

• Urinary beta-2-microglobulin (BMG) is not a suitable diagnostic parameter for identifying Minamata disease.
• Despite a dose-effect correlation in males, BMG's lack of discriminatory power limits its diagnostic value for methylmercury poisoning.